Moderna, Inc. - Common Stock (MRNA)

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.

Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Thursday. Discover the gap up and gap down stocks in the S&P500 index.

Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.

Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Monday after the company announced its new COVID-19 vaccine secured clearance from the U.S. Food and Drug Administration (FDA) for seniors and at-risk individuals.

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile.

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.

Investor sentiment on Moderna turned bearish over the weekend despite FDA approval of its new COVID-19 vaccine, mNEXSPIKE, which showed higher efficacy and a favorable safety profile.

Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Friday. Stay informed about the latest market trends.

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.

Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.

The Trump administration terminated a nearly $600 million award to Moderna for developing an mRNA-based bird flu vaccine, ending a key Biden-era pandemic preparedness initiative. The cancellation introduces uncertainty into the nation's defense strategy against H5N1 avian influenza despite positive clinical trial results.

The setback adds to recent regulatory delays, prompting cautious sentiment among retail investors expecting further downside.

RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.

Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top S&P500 gainers and losers in today's session.

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.

Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze

The company previously guided to a longer timeline for its Covid/flu shot. But Wednesday's news introduces some data risk.

Moderna will resubmit the application later this year after data from its ongoing late-stage trial of its seasonal flu vaccine is available.

After a sharp 23% rebound in the S&P 500 since April, hedge funds are now stacking record levels of bearish bets against stocks as investors question the staying power of the tariff-relief rally.